Esophageal squamous cell carcinoma. Pre-operative combined radiochemotherapy from a surgical oncological viewpoint;Plattenepithelkarzinom des ösophagus. Präoperative kombinierte radiochemo- therapie aus chirurgisch-onkologischer sicht

Chirurg

Volumn 80, Issue 11, 2009, Pages 1011-1018

  Brucher B L D M ^a  

^a Viszeral und Transplantationschirurgie   (Germany)

Author keywords

Esophageal carcinoma; Esophagus; Neoadjuvant therapy; Squamous cell carcinoma

Indexed keywords

ADJUVANT THERAPY; CANCER STAGING; DISEASE FREE SURVIVAL; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; HUMAN; MINIMAL RESIDUAL DISEASE; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PATIENT CARE TEAM; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS;

EID: 70449534813     PISSN: 00094722     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00104-009-1733-9     Document Type: Article

References (70)

1. Hulscher JB, van Sandick JW, de Boer AG et al (2002) Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 347(21):1662-1669
2. Brücher BLDM, Stein HJ, Werner M, Siewert JR (2001) Lymphatic vessel invasion is an independent prognostic factor in patients with a prima-ry resected tumor with esophageal squamous cell carcinoma. Cancer 92(8):2228-2233
3. Jin J, Liao Z, Zhang Z et al (2004) Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradi-otherapy followed by surgery. Int J Radiat Oncol Biol Phys 60(2):427-436
4. Siewert JR, Stein H (1998) Classification of carcinoma of the oesophagogastric junction. Br J Surg 85:1457-1459
5. Brücher BLDM, Swisher S, Königsrainer A et al (2009) Response to preoperative therapy in upper gastrointestinal cancers. Ann Surg Oncol 16(4):878-886
6. Siewert JR, Feith M, Stein H (2005) Esophagectomy as therapeutic principle for squamous cell esophageal cancer. Chirurg 76:1033-1043
7. Siewert JR, Feith M, Werner M, Stein H (2000) Adenocarcinoma of the esophagogastric junction. Results of surgical therapy based on anatomical/topo-graphic classification in 1,002 consecutive patients. Ann Surg 232:353-361
8. Jemal A, Murray T, Ward E et al (2005) Cancer statistics. CA Cancer J Clin 55(1):10-30
9. Siewert JR, Stein HJ, Feith M et al (2001) Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 234(3):360-369
10. Schneider JH, Küper M, Königsrainer A, Brücher BLDM (2009) Transient lower esophageal sphincter relaxation and consecutive esophageal motor response in humans and in an animal model. Obes Surg 19(5):595-600
11. Schneider JH, Küper M, Königsrainer A, Brücher BLDM (2009) Transient lower esophageal sphincter relaxation and consecutive esophageal motor response. J Surg Res (in press)
12. Stahl M, Stuschke M, Lehmann N et al (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell cell carcinoma of the esophagus. J Clin Oncol 23(10):2310-2317
13. Bosset JF, Gignoux M, Triboulet JP et al (1997) Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337(3):161-167
14. Burmeister BH, Smithers BM, Gebski V et al (2005) Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 6(9):659-668
15. Le Prise E, Etienne PL, Meunier B et al (1994) A randomized study of chemotherapy, radiation therapy and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 73(7):1779-1784
16. Nygaard K, Hagen S, Hansen HS et al (1992) Preoperative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 16(6):1104-1110
17. Urba SG, Orringer MB, Turrisi A et al (2001) Randomized trial of preoperative chemoradiation versus s0075rgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19(2):305-313
18. Walsh TN, Noonan N, Hollywood D et al (1996) A comparison of multimodal therapy and surgery for esophageal adenocarcinoma [see comments] 341(5):384]. N Engl J Med 335(7):462-467. Erratum: N Engl J Med 1999 Jul 29
19. Kelsen DP, Ginsberg R, Pajak TF et al (1998) Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339(27):1979-1984
20. Roth JA, Pass HI, Flanagan MM et al (1988) Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 96(2):242-248
21. Stahl M, Walz MK, Stuschke M et al (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27(6):851-856
22. Siewert JR, Feith M, Stein H (2005) Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographicanatomic subclassification. J Surg Oncol 90:139-146
23. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207-214
24. Moertel CG, Hanley JA (1976) The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 38(1):388-394
25. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
26. Brown WA, Thomas J, Gotley D et al (2004) Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy. Br J Surg 91(2):199-204
27. Cerfolio RJ, Bryant AS, Ohja B et al (2005) The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission to mography with computed tomography and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg 129(6):1232-1241
28. Lightdale CJ, Kulkarni KG (2005) Role of endoscopic ultrasonography in the staging and follow-up of esophageal cancer. J Clin Oncol 23(20):4483-4429
29. Griffith JF, Chan AC, Chow LT et al (1999) Assessing chemotherapy response of squamous cell oesophageal carcinoma with spiral CT. Br J Radiol 72(859):678-684
30. Jones DR, Parker LA Jr, Detterbeck FC, Egan TM (1999) Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 85(5):1026-1032
31. Westerterp M, van Westreenen HL, Reitsma JB et al (2005) Esophageal cancer: CT, endoscopic US and FDG PET for assessment of response to neoadjuvant therapy systematic review. Radiology 236(3):841-851
32. Beer AJ, Wieder HA, Lordick F et al (2006) Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neo-adjuvant chemotherapy. Radiology 239(2):472-480
33. Brücher BLDM, Stein HJ, Zimmermann F et al (2004) Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol 30(9):963-971
34. Port JL, Lee PC, Korst RJ et al (2007) Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma. Ann Thorac Surg 84:393-400
35. Hayano K, Okazumi S, Shuto K et al (2007) Perfusion CT can predict the response to chemoradiation therapy and survival in esophageal squamous cell carcinoma: initial clinical results. Oncol Rep 18(4):901-908
36. Wittekind C, Compton CC, Greene FL, Sobin LH (2002) TNM residual tumor classification revisited. Cancer 94:2511-2516
37. Mandard AM, Dalibard F, Mandard JC et al (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73(11):2680-2686
38. Brücher BLDM, Becker K, Lordick F et al (2006) The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 106(10):2119-2127
39. Brücher BLDM, Weber W, Fink U et al (1998) FDGPET in the response evaluation after neoadjuvant therapy in esophageal cancer. J Cancer Res Clin Oncol 124 [Suppl 2]:26
40. Brücher BLDM, Weber W, Bauer M et al (2001) Neoadjuvant therapy of esophageal squamous cell carcinoma: Response Evaluation by positron emission tomography. Ann Surg 233(3):300-309
41. Schneider PM, Baldus SE, Metzger R et al (2005) Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg 242(5):684-692
42. Becker K, Mueller JD, Schulmacher C et al (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98(7):1521-1530
43. Law S, Kwong DL, Wong KH et al (2006) The effects of neoadjuvant chemoradiation on pTNM staging and its prognostic significance in esophageal cancer. J Gastrointest Surg 10(9):1301-1311
44. Swisher S, Erasmus J, Masih M et al (2004) 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101(8):1776-1785
45. Wieder H, Brücher BLDM, Zimmermann F et al (2004) Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22(5):900-908
46. Ott K, Weber WA, Lordick F et al (2006) Metabolic imaging predicts response, survival and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24(29):4692-4698
47. Lordick F, Ott K, Krause B et al (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the Municon phase II trial. Lancet Oncol 46(6):263-270
48. Taylor MD, Smith PW, Brix WK et al (2009) Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer. Eur J Cardiothorac Surg 35(4):699-705
49. Brücher BLDM, Sarbia M, Oestreicher E et al (2007) Squamous cell carcinoma and Zenker Diverticulum. Dis Esophagus 20:75-58
50. Ott K, Lordick F, Molls M et al (2009) Limited resection and free jejunal graft interposition for squamous cell carcinoma of the cervical oesophagus. Br J Surg 96(3):258-266
51. Lewis I (1945) Carcinoma of the esophagus. Radical resection with oesophagogastrostomy for a midthoracic growth by right transpleural approach. J R Soc Med 38:482-483
52. Hulscher JB, van Sandick JW, de Boer AG et al (2002) Extrended thransthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 347(21):1662-1669
53. Omloo JM, Lagarde SM, Hulscher JB et al (2007) Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 246(6):992-1000
54. Tabira Y, Sakaguchi T, Kuhara H et al (2004) The width of a gastric tube has no impact on outcome after esophagectomy. Am J Surg 187(3):417-421
55. Schröder W, Vallbohmer D, Bludau M et al (2008) The resection of the azygos vein necessary or redundant extension of transthoracic esophagectomy? J Gastrointest Surg 12:1163-1167
56. Palanivelu C, Prakash A, Senthilkumar R et al (2006) Minimally invasive esophagectomy: thoracoscopic mobilization of the esophagus and mediastinal lymphadenectomy in prone position-experience of 130 patients. J Am Coll Surg 203(1):7-16
57. Udagawa H, Akiyama H (2001) Surgical treatment of esophageal cancer: Tokyo experience of the three-field technique. Dis Esophagus 14(2):110-114
58. Tachibana M, Kinugasa S, Yoshimura H et al (2003) Extended esophagectomy with 3-field lymph node dissection for esophageal cancer. Arch Surg 138(12):1383-1389
59. Lerut T, Nafteux P, Moons J (2004) Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival and outcome: a plea for adaption of TNM classification n upper-half esophageal carcinoma. Ann Surg 240(6):962-972
60. Nakamura M, Kido Y, Hosoya A et al (2007) Postoperative gastrointestinal dysfunction after 2-field versus 3-field lymph node dissection in patients with esophageal cancer. Surg Today 37(5):379-382
61. Bartels H, Stein HJ, Siewert JR (1998) Preoperative risk analysis and postoperative mortality of oesophagectomy for resectable oesophageal cancer. Br J Surg 85:840-844
62. Kilic A, Schuchert MJ, Pennathur A et al (2009) Impact on morbid obesity on perioperative outcomes of minimally invasive esophagectomy. Ann Thorac Surg 87:412-415
63. Wright CD, Kucharczuk JC, O'Brien SM et al (2009) Society of thoracic surgeons general thoracic surgery database. J Thorac Cardiovasc Surg 137(3):587-595. Erratum: J Thorac Cardiovasc Surg 137(6):1581
64. Murthy SC, Law S, Whooley BP et al (2003) Atrial fibrillation after esophagectomy is a marker for postoperative morbidity and mortality. J Thorac Cardiovasc Surg 126(4):1162-1167
65. Rohatgi PR, Swisher SG, Correa AM et al (2005) Comparison of clinical stage, therapy response and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagus. Int J Gastrointest Cancer 36(2):69-76
66. Kitajima M, Kitagawa Y (2002) Surgical treatment of esophageal cancer the advent of the era of individualization. N Engl J Med 347(21):1705-1709
67. Duong CP, Hicks RJ (2006) FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer. Eur J Nucl Med Mol Imaging 33(7):770-778
68. Perez EA, Bawejy M (2008) HER2-positive breast cancer: current treatment strategies. Cancer Invest 26(6):545-552
69. Sarbia M, Pühringer-Oppermann F, Brücher BLDM (2007) The predicitve value of molecular markers (p53, EGFR, ATM, CHK2) in multimodal treated esophageal squamous cell carcinoma. Br J Cancer 97(19):1404-1408
70. Brücher BLDM, Keller G, Werner M et al (2009) Using Q-RT-PCR to measure Cyclin D1, TS, TP, DPD, and Her-2/neu as predictors for response, survival and recurrence in patients with esophageal squamous cell carcinoma following radiochemotherapy. Int J Colorectal Dis 24(1):69-77